Research Article
Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer
Table 4
The prognostic value of the mRNA expression of ERCC in HER2 status GC patients.
| Genes | HER2 status | cases | HR (95% CI) | P-value |
| ERCC1 | negative | 298 | 0.75 (0.56–1.01) | 0.054 | | positive | 295 | 0.71 (0.51–0.98) | 0.039 | ERCC2 | negative | 298 | 0.76 (0.56–1.03) | 0.073 | | positive | 295 | 0.72 (0.54–0.95) | 0.022 | ERCC3 | negative | 298 | 0.8 (0.59–1.09) | 0.15 | | positive | 295 | 1.45 (1.1–1.92) | 0.0075 | ERCC4 | negative | 298 | 1.27 (0.94–1.72) | 0.11 | | positive | 295 | 1.52 (1.13–2.05) | 0.0059 | ERCC5 | negative | 298 | 0.86 (0.64–1.14) | 0.29 | | positive | 295 | 1.45 (1.1–1.9) | 0.0082 | ERCC6 | negative | 298 | 1.22 (0.92–1.62) | 0.18 | | positive | 295 | 1.27 (0.94–1.71) | 0.11 | ERCC8 | negative | 195 | 0.79 (0.54–1.15) | 0.21 | | positive | 153 | 1.8 (1.19–2.74) | 0.0052 |
|
|
Notes. ERCC, excision repair cross-complementing; GC, gastric cancer; HR, hazard ratio; CI, confidence interval.
|